Skip to main content

March 2016, Vol 9, Seventh Annual Payers' Guide

FDA Approvals, Payers' Guide
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
Loretta Fala
Read More
FDA Approvals, Payers' Guide
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus
Lisa A. Raedler, PhD, RPh
Read More
Page 4 of 5
Results 31 - 40 of 43